ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2025
Real-world impact of intrathecal baclofen therapy: the benefits of neteka on patient outcomes, caregiver burden, and cost efficiency.
Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Efficacy and Safety of Baclofen 40 mg/20 mL in an Intrathecal Infusion System.Life (Basel, Switzerland) · 2026Article
- High-Frequency Spinal Cord Stimulation for the Treatment of Spasticity: A Preliminary Case Series.Brain sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIntrathecal baclofen therapy (ITB) is a well-established treatment modality for severe spasticity, but it is burdened by the need for periodic pump refills. The introduction of a new formulation of baclofen with an extended stability of 180 days (Neteka, Nordic Group BV) could decrease the frequency of refills. We aimed at analyzing the clinical and economic impact of Neteka introduction in our outpatient facility.
methodsForty-eight patients with an implanted device for intrathecal baclofen infusion, who shifted from standard baclofen to Neteka, were included in the present study. We collected clinical and refilling data both from pre-Neteka and Neteka timeframes.
resultsIn patients treated with baclofen 2 mg/ml (45/48, 93.8%), the introduction of Neteka led to a significant decrease of median number of refills per year (2.7 vs. 4 in pre-Neteka timeframe, p < 0.0001). This resulted in an improved quality of life, as shown by the reduction of Oberst Caregiving Burden Scale score both for time and difficulty of caregiving (p < 0.0001 and p = 0.0003, respectively). Furthermore, a median saving of 302.40 euro per year per patient, as compared to pre-Neteka timeframe, was registered. Similar results were obtained in the smaller cohort treated with baclofen 0.5 mg/ml (3/48, 6.3%). Neteka appreciation rate was high. As expected, no changes in clinical effectiveness of ITB therapy were observed by comparing pre-Neteka and Neteka timeframes.
conclusionsThe extended half-life provided by Neteka, by reducing the number of refills, could improve patient quality of life, enhance caregiver satisfaction, and decrease the financial burden on healthcare system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.